FOLH1 and neoplasm: Using a similar strategy, Busslinger et al. developed ibuprofen containing ligand [225Ac]Ac-SibuDAB, which showed similar radiolabeling and hematological effect as [225Ac]Ac-PSMA-617, whereas the tumor uptake of the [225Ac]Ac-SibuDAB doubled at 48 h as compared to [225Ac]Ac-PSMA-617 (64 ± 11% IA/g vs. 31 ± 3% IA/g), resulting in improved therapeutic response and overall survival in animal models 30.